Ocumension Therapeutics (HKG:1477) enrolled the first patient in a phase III clinical trial of OT-802 (pilocarpine hydrochloride) in China, according to a Thursday Hong Kong bourse filing.
The drug has been developed for the treatment of presbyopia, the ophthalmic pharmaceuticals maker said.
Tianjin Jinrong Tianyu Precision Machinery (SHE:300988) invested 4 million yuan for a 3.69% stake in Jiaxing Shanghe Sutong Equity Investment Partnership, according to a Thursday filing with the Shenzhen bourse.The fund, with a target subscription scale of 108.3 million yuan, will solely invest in Beijing Huixi Intelligent Information Technology, an embodied artificial intelligence chip and controller maker.Shares of the mold products maker closed 4% higher.
SWCC (TYO:5805) has agreed to transfer all 6,200 shares it holds in AXIO Corp., a wholly owned consolidated subsidiary, to Yokogawa Rental & Lease, with the share transfer agreement concluded on May 27, and the transaction scheduled for July 1, subject to clearance under the Japanese Anti-monopoly Act.The decision to transfer AXIO, an IT solutions company specializing in cloud-based ID management services under the Keyspider brand, forms part of SWCC's business portfolio reforms under its Medium-term Management Plan, according to a Tokyo bourse filing on Thursday.The transfer price has not been disclosed under the agreement with the counterparty, though SWCC expects to record a profit from the transaction and is currently assessing the impact on its net profit.
Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's TQB3454 tablet was included in the priority review list by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The drug is indicated for the treatment of patients with locally advanced, recurrent and/or metastatic biliary tract cancer harboring IDH1 mutations.